Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262330 | 0.84 | — | — | |
| SCHEMBL573387 | 0.78 | — | — | |
| SCHEMBL6809037 | 0.76 | — | — | |
| SCHEMBL4782317 | 0.73 | NPC1 (0.46) | NPC1RAB9AKMT2ABRAFHDAC1 | |
| SCHEMBL7110299 | 0.73 | NPC1 (0.42) | NPC1RAB9AKMT2ABRAFHDAC1 | |
| SCHEMBL538187 | 0.73 | NPC1 (0.39) | NPC1RAB9AKMT2ASMN1; SMN2HTT | |
| SCHEMBL738628 | 0.73 | — | — | |
| SCHEMBL1261544 | 0.72 | — | — | |
| SCHEMBL1324 | 0.72 | NPC1 (0.62) | NPC1RAB9AKMT2ABRAFHDAC1 | |
| SCHEMBL2004766 | 0.72 | NPC1 (0.52) | NPC1RAB9AKMT2ABRAFHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | claimed |
| US-20210369849-A1 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | EBETINO FRANK HALLOCK (US) | 2021-12-02 | — | — | US | claimed |
| EP-3813840-A1 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | Ebetino, Frank Hallock (US) | 2021-05-05 | — | — | EP | claimed |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | claimed |
| US-20190169214-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2019-06-06 | — | — | US | claimed |
| EP-3464307-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | Biovinc, LLC. (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2017210611-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC, LLC. (US) | 2017-12-07 | — | — | WO | claimed |
| US-4558034-A | Inhibitors of bacterial collagenase | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF KENTUCKY (US) | 1985-12-10 | — | — | US | claimed |
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210369849-A1 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | EBETINO FRANK HALLOCK (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3820565-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | Biovinc, LLC. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3813840-A1 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | Ebetino, Frank Hallock (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | disclosed |
| US-20190169214-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2019-06-06 | — | — | US | disclosed |
| EP-3464307-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | Biovinc, LLC. (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210611-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC, LLC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-5500414-A | TREATMENT OF PERIODONTAL DISESASE, INHIBITION OF ZINC METALLOPROTEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1996-03-19 | — | — | US | disclosed |
| US-5389612-A | Treating infections caused by clostridium histolyticum and pseudomonas aeruginosa; enzyme inhibitors | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1995-02-14 | — | — | US | disclosed |
| US-4558034-A | Inhibitors of bacterial collagenase | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF KENTUCKY (US) | 1985-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169214-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | NPC1 1539/4885RAB9A 174/4885KMT2A 4250/4885 |
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | NPC1 1539/4885RAB9A 174/4885KMT2A 4250/4885 |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | NPC1 1539/4885RAB9A 174/4885KMT2A 4250/4885 |
| US-20210369849-A1 | BONE TARGETED ANTIMICROBIAL OXAZOLIDINONE RELATED COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | SOST, BPGM, PTMS | NPC1 2899/4885RAB9A 825/4885KMT2A 4628/4885 |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | NPC1 1539/4885RAB9A 174/4885KMT2A 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.